Leading Pharmacology Journals

Publications of the American Society for Pharmacology and Experimental Therapeutics, Inc.

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Editor: Eva King Killam, PhD
JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology. Monthly

DRUG METABOLISM AND DISPOSITION
The Biological Fate of Chemicals
Editor: Vincent G. Zannoni, PhD
DRUG METABOLISM AND DISPOSITION publishes in vitro and in vivo experimental results that bring readers significant and original information on xenobiotic metabolism and disposition, including metabolism of all pharmacologic agents or drugs and environmental chemicals, reactants, and preservatives. The areas covered are pharmacokinetics, pharmacodynamics, and mechanisms such genetic, nutritional, or hormonal factors affecting the biological fate of chemicals toxicological consequences of xenobiotic metabolism. Bimonthly

PHARMACOLOGICAL REVIEWS
Editor: James A. Bain, PhD
PHARMACOLOGICAL REVIEWS is a showcase for important review articles in your field, featuring longer papers on topics of high current interest. The areas covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription. Quarterly

YES! Enter my subscriptions to the following:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscriptions today!

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (monthly)
- Individual: $140/yr
- Institutions: $220/yr
- (Please add $30.00 outside the U.S.)
- New Subscription
- Renewal
- 3 yrs $100
- 2 yrs $75
- 1 yr $50

DRUG METABOLISM AND DISPOSITION (bimonthly)
- Individual: $60/yr
- Institutions: $95/yr
- (Please add $10.00 outside the U.S.)
- New Subscription
- Renewal
- 3 yrs $45
- 2 yrs $30
- 1 yr $15

MOLECULAR PHARMACOLOGY (monthly)
- Individual: $75/yr
- Institutions: $165/yr
- (Please add $15.00 outside the U.S.)
- New Subscription
- Renewal
- 3 yrs $60
- 2 yrs $45
- 1 yr $30

PHARMACOLOGICAL REVIEWS (quarterly)
- Individual: $35/yr
- Institutions: $70/yr
- In-training: $25/yr
- (Please add $10.00 outside the U.S.)
- New Subscription
- Renewal
- 3 yrs $25
- 2 yrs $20
- 1 yr $15

Payment options:
- [ ] Check enclosed
- [ ] Bill me
- [ ] VISA
- [ ] MasterCard
- [ ] American Express

signature/P.O. #

MD residents, please add 5% sales tax. Subscriptions from outside the U.S. and Canada must be prepaid, in U.S. dollars only. Rates valid for orders received before October 31, 1987.

Please allow 10 weeks for delivery of your latest issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Annual rates available upon request. Residents, fellows, interns, and students, when requesting the in-training rate (to which you are entitled for 3 years), please specify training status and institution.

Rates subject to change without notice.

P.O. Box 233291
Baltimore, Maryland 21203
266 Fulham Road
London SW10 9EL, England

ASPETAD 93180 87
INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of $30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to Dr. William A. Catterall, Editor, Molecular Pharmacology, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.

The expenses associated with the review of manuscripts submitted to Molecular Pharmacology and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. Therefore, all manuscripts must be accompanied either by a check for $30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ x 11 inches (ca. 215 x 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made. Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in Molecular Pharmacology represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in Molecular Pharmacology. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.
All manuscripts that require major revisions or that do not fit the
criteria for Accelerated Communications will be returned to authors
for revision and further consideration as a regular paper. Such
manuscripts will retain the original submission date if revised
versions are received in a timely manner.

Accelerated Communications may be submitted in the same style
as regular manuscripts. Results and Discussion may be combined
at the discretion of the authors. Manuscripts must not exceed five
printed pages in the journal. This corresponds approximately to 25
double-spaced typewritten pages (1-inch margins) including all com-
ponents of the manuscript and counting each figure as a page of
typewritten text. Manuscripts that are judged to be too long will be
considered as regular papers.

Organization and style of manuscripts. The policy of the Journal
is to allow authors maximum freedom in organizing and presenting
their material, and in expressing their ideas, provided only that
clarity and conciseness are achieved. For most manuscripts, the
most suitable format is: (1) Summary, (2) Introduction, (3) Mate-
rials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathemat-
ical formulas and abbreviations should follow the Instructions to
Authors of the Journal of Biological Chemistry (Vol. 261, pp. 1–11,
January 10, 1986). Drugs must be referred to by their generic or
chemical names throughout the text, but may be identified by trade
name in parentheses or a footnote. The systematic name and
number given by the Commission on Enzymes of the International
Union of Biochemistry should be included for each enzyme of
importance in a paper, at the point in the Summary or Introduction
where the enzyme is first mentioned. The use of abbreviations
should be minimized and abbreviations avoided in the Summary.
All essential abbreviations should be defined in a single footnote
when first introduced. Abbreviations of journal names should con-
form to the style of Biological Abstracts. References to papers that
have been accepted for publication, but have not appeared, should
be cited like other references with the abbreviated name of the
journal followed by the words "in press." Copies of such papers
should be sent whenever the findings described in them have a
direct bearing on the paper being submitted for publication. "Per-
sonal Communications" and "Unpublished Observations" should
be cited in footnotes to the text and should not be included in the
reference list.

A manuscript should include the following, in the order listed: (1)
Title. Numbered footnotes to the title should be avoided; acknowl-
edgment of financial support should be given in an unnumbered
footnote to the title. (2) Names of authors, their laboratory and
institution. (3) A running title, not exceeding 60 characters and
spaces. (4) Summary. (5) Text. Footnotes should be referred to by
superscript numbers and references by numbers in parentheses. (6)
References, numbered according to order of citation in the text,
including title and complete pagination. Examples: 1. Goren, J. H.,
L. G. Baus, and W. Vale. Forces and structural limitations of
binding of thyrotropin-releasing receptor: the pyrogallat acid
T. O'Brian. Overview of catecholamines in selected endocrine sys-
tems, in Norepinephrine (M. G. Ziegler and C. R. Lake, eds.).
W., and W. G. Cochran. Statistical Methods. Iowa State University
Press, Ames (1967). (7) Footnotes, numbered according to order of
appearance in the text. (8) Tables. (9) Figures. (10) Legends to
figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and
designed to fit the single-column width of the full-page width. Every
table should have an explanatory title and sufficient experimental
detail in a paragraph following the title to be intelligible without
references to the text (unless the procedure is given in the Methods
section, or under another table or figure). Footnotes to tables should
appear beneath the tables themselves and should be designated by
lower-case italic superscript letters, a, b, c, etc.

Figures. These should be numbered with arabic numerals. Each of
the four manuscript copies should contain all of the figures. Only
the original set need be of quality suitable for reproduction except
in the case of half-tones, which require four sets of photographs or
original drawings. These should be unmounted glossy photographs
(or original India-ink drawings). Usually figures will be reduced to
one column width (85 mm) and all numbers after such reduction
should be at least 1.5 mm high. The figures must be ready, in all
respects, for direct reproduction: no lettering or other art work will
be done by the publisher. If symbols are not explained on the face
of the figure, only standard characters, of which the printer has
type, may be used (×, ○, ●, □, ■, △, ▽, ●). The back of each
photograph should bear its number, and the legend TOF at the
appropriate edge. The list of legends for the figures should give
captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page
proof. The Editors are very much interested in having accepted
contributions appear in the earliest possible issue of the Journal,
and therefore request that galley proof be returned within 24 hours
after its receipt. In exceptional cases, a "Note added in proof" may
be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as
information on the estimation of page charges will be mailed with
galley proof. Please direct questions on reprints, page charges, or
other business matters to Kay Croker, Executive Officer, American
Society for Pharmacology and Experimental Therapeutics, 9650
Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.